Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RERevelation Biosciences, Inc. logo

Revelation Biosciences, Inc. (REVB)

NASDAQ Capital Market · Currency in USD
$3.79 ▲ +0.11 (+2.99%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.83 ▲ +0.04 (+1.06%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.68
Open
$3.76
Day's Range
$3.66 – $3.88
52 Week Range
$3.08 – $40.60
Volume
16,224
Avg. Volume
9,331
Market Cap
$2.16M
Beta (5Y Monthly)
-0.17
PE Ratio (TTM)
--
EPS (TTM)
-$19.65
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Revelation Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
8
CEO
James Rolke

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$6.16
DateEst.Actual
Aug 7, 2026-$6.13-$6.09Beat
May 7, 2026-$8.05-$2.71Beat
Mar 5, 2026-$9.87-$1.65Beat
Nov 7, 2025-$9.38-$7.08Beat
Aug 8, 2025-$31.22-$28.04Beat
May 9, 2025-$48.16-$25.32Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on REVB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.